Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crossing The 'Valley Of Death': Breakthrough Devices Rule Could Lead To Slew Of New Products

Executive Summary

A new proposed rule would give automatic new technology add-on payments to breakthrough devices. While it may affect only a very small sector of the industry, the lobby group AdvaMed says it is a good first step to getting broader coverage for all devices and will incentivize companies to invest in breakthrough device research.

You may also be interested in...



CMS Mulls Proposal For Breakthrough Devices Almost One Year After MCIT Scrapped

A CMS official announced that the agency is working on a proposal to replace breakthrough device coverage scheme MCIT  that will balance ensuring product safety with narrowing the “valley of death.”

CMS Pauses The Clock On Implementing Highly Anticipated Medical Device Reimbursement Rule

The rule was set to go into effect 15 March, but the government is delaying it for at least two months to discuss the resources needed for the payments – and whether they’re the right policy to start with.

Game-Changer? CMS Proposes Rule To Cover Breakthrough Devices On Provisional Basis

The long-awaited proposed rule from the US Medicare agency would allow breakthrough products approved by the FDA to get reimbursed, while manufacturers continue to collect clinical and real-world data.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125005

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel